Abbott has announced that the US Food and Drug Administration (FDA) has approved the company’s TactiFlex Ablation Catheter, Sensor Enabled, which features a flexible tip and contact force technology.
Used to perform an ablation procedure to treat atrial fibrillation (AF), the most common abnormal heart rhythm, the TactiFlex catheter can result in reduced procedure times and better safety when compared to the company’s previous generation catheters, the company said in a press release.
“For those suffering from AF, daily life can be challenging as people often feel dizziness, chest pain and heart palpitations. AF can lead to stroke if left untreated, making it critical for physicians to treat the issue as early as possible,” said Larry A Chinitz (NYU Langone Heart, New York, USA). “We are entering the next chapter of AF ablation with new tools such as Abbott’s TactiFlex that, when used with mapping systems to accurately identify the source of an arrhythmia, can safely and efficiently treat the problem in ways we never thought possible a decade ago.”
